Investing

Acquired in-process research and development

Year-over-year, this metric declined by 100.0%, from $3.46B to $0.00. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025

How to read this metric

High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.

Detailed definition

Acquired In-Process Research and Development (IPR&D) represents the cash paid to acquire research projects that have not...

Peer comparison

A hallmark metric for pharmaceutical and biotech firms relying on external innovation.

Metric ID: cf_acquired_ipr_d

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$0.00$0.00$0.00$0.00$0.00$0.00$0.00$1.19B$0.00$0.00-$1.19B$0.00$0.00$0.00$3.46B$0.00$0.00$0.00$0.00
QoQ Change-100.0%+100.0%-100.0%
YoY Change-100.0%+389.9%-100.0%
Range-$1.19B$3.46B
Avg YoY Growth+63.3%
Median YoY Growth-100.0%

Acquired in-process research and development at Other Companies

Frequently Asked Questions

What is Merck & Co.'s acquired in-process research and development?
Merck & Co. (MRK) reported acquired in-process research and development of $0.00 in Q4 2025.
How has Merck & Co.'s acquired in-process research and development changed year-over-year?
Merck & Co.'s acquired in-process research and development decreased by 100.0% year-over-year, from $3.46B to $0.00.
What does acquired in-process research and development mean?
Cash spent to buy research and development projects from other companies.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.